What's Happening?
Scribe Therapeutics, a biotechnology company specializing in CRISPR-based technologies, has received regulatory clearance from the Australian Therapeutic Goods Administration to begin a first-in-human
clinical study of STX-1150. This novel therapy aims to reduce low-density lipoprotein cholesterol (LDL-C) levels by epigenetically silencing the PCSK9 gene, a key factor in atherosclerotic cardiovascular disease (ASCVD). The therapy is designed to provide long-term LDL-C reduction without permanently altering DNA. The Phase 1 study will assess the safety, tolerability, and pharmacodynamics of STX-1150 in adults with elevated LDL-C at increased cardiovascular risk. The trial will be conducted in Australia and New Zealand, with up to 64 participants monitored for one year post-treatment.
Why It's Important?
The development of STX-1150 represents a significant advancement in the treatment of hypercholesterolemia, a major contributor to cardiovascular disease, which is the leading cause of death globally. Current lipid-lowering therapies often require ongoing administration and face adherence challenges. STX-1150's potential to provide sustained LDL-C reduction with a single dose could redefine the standard of care, offering a more practical and durable solution for patients. This innovation could reduce the treatment burden and improve long-term cardiovascular health outcomes, addressing a critical need in the management of ASCVD.
What's Next?
The Phase 1 clinical trial will proceed with an open-label, single ascending dose design, followed by a dose expansion phase. Participants will be enrolled at Monash Health's Victorian Heart Hospital in Australia, under the leadership of cardiologist Dr. Stephen Nicholls. The trial's outcomes will be closely monitored to evaluate the therapy's efficacy and safety. Scribe Therapeutics plans to present preclinical data at the European Atherosclerosis Society Congress, potentially paving the way for further clinical development and eventual regulatory approval.
